LONDON, Aug 19 (Reuters) - A keenly awaited new lupus drug from GlaxoSmithKline Plc (GSK.L) and Human Genome Sciences Inc (HGSI.O) will get a priority review from U.S. regulators, potentially clearing the way for its approval by mid-December.
LONDON, Aug 19 (Reuters) - A keenly awaited new lupus drug from GlaxoSmithKline Plc (GSK.L) and Human Genome Sciences Inc (HGSI.O) will get a priority review from U.S. regulators, potentially clearing the way for its approval by mid-December.
